Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)

被引：0

作者：

Wei, J. C. C. ^{[1
]}

Baeten, D. ^{[1
]}

Sieper, J. ^{[1
]}

Deodhar, A. ^{[1
]}

Bhosekar, V ^{[1
]}

Martin, R. ^{[1
]}

Porter, B. ^{[1
]}

机构：

[1] Novartis Pharmaceut, E Hanover, NJ USA

来源：

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2017年 / 20卷 / 07期

关键词：

D O I：

10.1111/1756-185X.13154

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：911 / 911

页数：1

共 50 条

[21] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF inhibitors: 52-week Results from a Phase 3 Study
Genovese, Mark
Helliwell, Philip
Combe, Bernard
Kremer, Joel
Adams, David
Lee, Chin
Kerr, Lisa
Nash, Peter
Rahman, Proton
[J]. JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 996 - 996
[22] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Genovese, Mark C.
Combe, Bernard
Kremer, Joel
Adams, David
Lee, Chin
Kerr, Lisa
Nash, Peter
[J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
[23] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Genovese, M. C.
Combe, B.
Kremer, J.
Adams, D. H.
Lee, C.
Kerr, L.
Nash, P.
Garcia, E. G.
[J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S158 - S158
[24] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Genovese, M. G.
Combe, B.
Kremer, J.
Adams, D.
Lee', C.
Kerr, L.
Nash, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1035 - 1036
[25] Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
Braun, Juergen
Deodhar, Atul A.
Sieper, Joachim
Dougados, Maxime
Porter, Brian
Andersson, Mats
Richards, Hanno
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[26] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
Mease, Philip J.
Okada, Masato
Kishimoto, Mitsumasa
Shuler, Catherine L.
Carlier, Hilde
Lin, Chen-Yen
Mou, Jiani
Moriarty, Susan R.
Lee, Chin H.
Gladman, Dafna D.
[J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
[27] Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5
Huang Feng
Sun Fei
Wan Wei-Guo
Wu Li-Jun
Dong Ling-Li
Zhang Xiao
Kim Tae-Hwan
Sengupta Raj
?enolt Ladislav
Wang Yi
Qiu Hao-Min
Porter Brian
Haemmerle Sibylle
[J]. 中华医学杂志(英文版), 2020, (21) : 2521 - 2531
[28] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka
Alan Kivitz
Eva Dokoupilova
Ricardo Blanco
Marco Maradiaga
Hasan Tahir
Luminita Pricop
Mats Andersson
Aimee Readie
Brian Porter
[J]. Arthritis Research & Therapy, 19
[29] Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5
Huang, Feng
Sun, Fei
Wan, Wei-Guo
Wu, Li-Jun
Dong, Ling-Li
Zhang, Xiao
Kim, Tae-Hwan
Sengupta, Raj
Senolt, Ladislav
Wang, Yi
Qiu, Hao-Min
Porter, Brian
Haemmerle, Sibylle
[J]. CHINESE MEDICAL JOURNAL, 2020, 133 (21) : 2521 - 2531
[30] Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Pavelka, Karel
Kivitz, Alan
Dokoupilova, Eva
Blanco, Ricardo
Maradiaga, Marco
Tahir, Hasan
Pricop, Luminita
Andersson, Mats
Readie, Aimee
Porter, Brian
[J]. ARTHRITIS RESEARCH & THERAPY, 2017, 19

← 1 2 3 4 5 →